TY - JOUR
T1 - Orexin A modulates prolactin production by regulating BMP-4 activity in rat pituitary lactotorope cells
AU - Fujisawa, Satoshi
AU - Komatsubara, Motoshi
AU - Ogura-Ochi, Kanako
AU - Tsukamoto-Yamauchi, Naoko
AU - Toma, Kishio
AU - Inagaki, Kenichi
AU - Wada, Jun
AU - Otsuka, Fumio
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research (No. 15K09434 and 18K08479 ), The Uehara Memorial Foundation (Japan) , Ofuji Endocrine Medical Award (Japan) , Ryobi Teien Memory Foundation Award (Japan) , and Forum on Growth Hormone Research Award (Japan) .
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - The impact of orexins on anterior pituitary function has yet to be clarified. We studied the effects of orexin A and its interaction with the bone morphogenetic protein (BMP) system on the regulatory role of prolactin synthesis using rat lactotrope GH3 cells expressing BMP-4. Orexin type 1 receptor (OX1R), but not type 2 receptor (OX2R), was predominantly expressed in GH3 cells. Orexin A suppressed forskolin-induced, but not basal, prolactin mRNA expression without reducing cAMP levels. Of note, orexin A suppressed BMP-4-induced prolactin mRNA and cAMP synthesis. Impairment of the effects of orexin by chemical inhibitors suggested involvement of the P38 pathway in the OX1R activity that suppresses BMP-4-induced PRL expression. Given that inhibition of BMP-receptor signaling reduced prolactin mRNA levels, endogenous BMP action is likely to be linked to the activation of prolactin synthesis by GH3 cells. Orexin A was revealed to suppress Smad1/5/9 phosphorylation and Id-1 transcription induced by BMP-4, which was restored in the presence of orexin-receptor antagonists, suggesting that the inhibitory effect of orexin A occurred via OX1R. Orexin A also reduced ALK-3 expression but increased inhibitory Smad6/7 expression, while BMP-4 treatment downregulated OX1R expression. These results indicated that orexin A plays an inhibitory role in prolactin production through suppression of endogenous BMP activity in GH3 cells, suggesting that a new functional role of the interaction between orexin and BMP-4 is modulation of prolactin levels in lactotrope cells.
AB - The impact of orexins on anterior pituitary function has yet to be clarified. We studied the effects of orexin A and its interaction with the bone morphogenetic protein (BMP) system on the regulatory role of prolactin synthesis using rat lactotrope GH3 cells expressing BMP-4. Orexin type 1 receptor (OX1R), but not type 2 receptor (OX2R), was predominantly expressed in GH3 cells. Orexin A suppressed forskolin-induced, but not basal, prolactin mRNA expression without reducing cAMP levels. Of note, orexin A suppressed BMP-4-induced prolactin mRNA and cAMP synthesis. Impairment of the effects of orexin by chemical inhibitors suggested involvement of the P38 pathway in the OX1R activity that suppresses BMP-4-induced PRL expression. Given that inhibition of BMP-receptor signaling reduced prolactin mRNA levels, endogenous BMP action is likely to be linked to the activation of prolactin synthesis by GH3 cells. Orexin A was revealed to suppress Smad1/5/9 phosphorylation and Id-1 transcription induced by BMP-4, which was restored in the presence of orexin-receptor antagonists, suggesting that the inhibitory effect of orexin A occurred via OX1R. Orexin A also reduced ALK-3 expression but increased inhibitory Smad6/7 expression, while BMP-4 treatment downregulated OX1R expression. These results indicated that orexin A plays an inhibitory role in prolactin production through suppression of endogenous BMP activity in GH3 cells, suggesting that a new functional role of the interaction between orexin and BMP-4 is modulation of prolactin levels in lactotrope cells.
KW - Bone morphogenetic protein
KW - Lactotrope
KW - Orexin
KW - Pituitary
KW - Prolactin
UR - http://www.scopus.com/inward/record.url?scp=85061193139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061193139&partnerID=8YFLogxK
U2 - 10.1016/j.peptides.2019.01.002
DO - 10.1016/j.peptides.2019.01.002
M3 - Article
C2 - 30721716
AN - SCOPUS:85061193139
SN - 0196-9781
VL - 113
SP - 35
EP - 40
JO - Peptides
JF - Peptides
ER -